Founded in 2016, MatchMiner is an open source computational platform developed by the Knowledge Systems Group at Dana-Farber Cancer Institute (DFCI) for matching patient-specific genomic profiles to cancer precision medicine trials. The main goals of MatchMiner are:
1. Accelerate trial enrollment onto cancer precision medicine trials.
2. Maximize potential trial options for all patients.
Core Components
Clinical Trial Markup Language (CTML)
Clinical Trial Markup Language (CTML) is a human readable markup language that allows users to structure clinical trial details including clinical and genomic eligibility.
CTML supports a wide range of clinical trial information and is easily extended to include new criteria. Eligibility criteria can include genomic, clinical, and demographics.
Modes of Use
MatchMiner provides 3 modes to match patients to precision medicine trials
Patient-Centric
This mode enables patient care providers and clinical research staff to view patient trial matches on an individual basis.
Trial-Centric
This mode enables trial staff to identify patients with specific genomic and clinical features that match a trial’s eligibility criteria.
Trial Search
This mode enables patient care providers and clinical research staff to view trials matches for individual patients. This mode requires manual evaluation of trial matches for each genomic alteration of interest.
Publications and Presentations
Publications
- Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression, JAMA Network, 2025
- MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching, arXiv, 2024
- MatchMiner: An open-source platform for cancer precision medicine, npj Precision Oncology, 2022
Presentations
Presentations
News
Out now on arXiv!
MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching
